Brokerages Set Edwards Lifesciences Corporation (NYSE:EW) Price Target at $96.45

Edwards Lifesciences Corporation (NYSE:EW) has been given a consensus rating of “Moderate Buy” by the twenty-eight research firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $96.8182.

EW has been the topic of a number of research analyst reports. Citigroup reissued a “buy” rating and issued a $101.00 price target (up from $96.00) on shares of Edwards Lifesciences in a research note on Thursday, December 11th. The Goldman Sachs Group restated a “buy” rating and set a $108.00 price target on shares of Edwards Lifesciences in a research note on Friday, January 9th. Wells Fargo & Company set a $100.00 price objective on Edwards Lifesciences in a research note on Thursday, December 18th. BTIG Research reissued a “buy” rating and set a $103.00 target price (up previously from $100.00) on shares of Edwards Lifesciences in a research note on Thursday, December 4th. Finally, Raymond James Financial upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 target price for the company in a report on Monday, November 3rd.

Insider Activity

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,386 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $83.76, for a total value of $953,691.36. Following the completion of the transaction, the vice president owned 38,970 shares of the company’s stock, valued at $3,264,127.20. This trade represents a 22.61% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Daniel J. Lippis sold 1,020 shares of the business’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $82.55, for a total transaction of $84,201.00. Following the completion of the transaction, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,816,265.10. This trade represents a 4.43% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 57,824 shares of company stock valued at $4,863,323. 1.29% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Edwards Lifesciences

Several institutional investors have recently modified their holdings of EW. JPL Wealth Management LLC acquired a new stake in Edwards Lifesciences in the third quarter valued at $25,000. Rosenberg Matthew Hamilton acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter worth about $28,000. True Wealth Design LLC raised its position in shares of Edwards Lifesciences by 251.5% during the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after acquiring an additional 259 shares in the last quarter. NewSquare Capital LLC lifted its stake in Edwards Lifesciences by 57.8% during the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after purchasing an additional 134 shares during the last quarter. Finally, Hantz Financial Services Inc. boosted its holdings in Edwards Lifesciences by 76.6% in the third quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 164 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Up 2.0%

NYSE EW opened at $85.12 on Monday. The business’s fifty day simple moving average is $85.08 and its 200-day simple moving average is $80.72. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. The firm has a market cap of $49.39 billion, a PE ratio of 36.69, a P/E/G ratio of 3.18 and a beta of 0.95. Edwards Lifesciences has a 52 week low of $65.94 and a 52 week high of $87.89.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The firm had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same period last year, the business earned $0.67 earnings per share. Edwards Lifesciences’s revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, equities analysts anticipate that Edwards Lifesciences will post 2.45 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.